ArticleDiscover oncology2025
Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCell division cycle 42 (CDC42) regulates prostate cancer growth and metastasis. This study aimed to evaluate the change in serum CDC42 during treatment and its association with the clinical features and prognosis in abiraterone plus prednisone treated metastatic castration-resistant prostate cancer (mCRPC) patients.
methodsSeventy-two mCRPC patients who underwent abiraterone plus prednisone therapy were included in this retrospective study, followed by the serum CDC42 level determination at baseline and month 2 (M2). Additionally, serum CDC42 was detected in thirty age-matched healthy controls (HCs).
resultsThe CDC42 level was higher in mCRPC patients versus HCs [median (interquartile range): 1012.5 (655.8-1671.3) versus 606.0 (392.0-1007.0) pg/mL] (P < 0.001). Meanwhile, the CDC42 level was associated with lymph node metastasis (P = 0.041) and visceral metastasis (P = 0.005), but not other clinical characteristics (P > 0.050) in mCRPC patients. Additionally, the CDC42 level was decreased after 2-month treatment (P < 0.001). Inspiringly, shorter radiographic progression-free survival (rPFS) was observed in mCRPC patients with CDC42 > 1000 pg/mL than in those with CDC42 ≤ 1000 pg/mL at baseline (P = 0.035). Furthermore, shorter rPFS (P = 0.002) and overall survival (P = 0.043) were discovered in mCRPC patients with CDC42 > 1000 pg/mL than in those with CDC42 ≤ 1000 pg/mL at M2. More importantly, CDC42 at M2 (> 1000 vs. ≤ 1000 pg/mL) was independently associated with shorter rPFS in mCRPC patients (P = 0.035, hazard ratio = 2.203).
conclusionThe serum CDC42 level associates with LNM, visceral metastasis, and worse prognosis in mCRPC patients underwent abiraterone plus prednisone therapy. However, future prospective, large-scale, and controlled studies are needed for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.